This is a preview of subscription content, log in via an institution to check access.
Notes
The study was supported by Shire Pharmaceuticals Iberica.
Reference
Giraldo P, et al. Cost-Utility of Velaglucerase Alpha for the Treatment of Type I Gaucher Disease in Spain. 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSY48, 18 May 2013.
Rights and permissions
About this article
Cite this article
Velaglucerase-α in type 1 Gaucher cost saving in Spain. PharmacoEcon Outcomes News 680, 2 (2013). https://doi.org/10.1007/s40274-013-0459-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0459-6